Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4722573 | 0.78 | XDH (0.53) | XDHMAPTALDH1A1 | |
| SCHEMBL4718942 | 0.77 | XDH (0.53) | XDHMAPT | |
| SCHEMBL4715888 | 0.75 | CETP (0.49) | XDHMAPT | |
| SCHEMBL29160382 | 0.70 | ELANE (0.45) | MAPTNPC1RAB9A | |
| SCHEMBL4720233 | 0.69 | XDH (0.56) | XDHMAPTALDH1A1 | |
| SCHEMBL4720977 | 0.68 | MYC (0.56) | MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL28250432 | 0.68 | XDH (0.64) | XDH | |
| SCHEMBL6683075 | 0.68 | NPC1 (0.68) | MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4720237 | 0.67 | XDH (0.54) | XDH | |
| SCHEMBL6664344 | 0.67 | MAPT (0.45) | MAPTALDH1A1NPC1RAB9AS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1452528-B1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | NIPPON CHEMIPHAR CO., LTD. | 2007-11-15 | — | — | US | disclosed |
| US-7253154-B2 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20050090472-A1 | Xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1452528-A1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090472-A1 | Xanthine oxidase inhibitors | XDH, CBR1, NOX1 | XDH 1/4885MAPT 4473/4885ALDH1A1 706/4885 |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | XDH, CBR1, NOX1 | XDH 1/4885MAPT 4411/4885ALDH1A1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.